Form 4 Tracker
Enliven Therapeutics, Inc.
ELVN

31 insider filings · Latest: Aug 4, 2026

Common Stock Transactions
Txn DateAcceptedInsiderTypeSharesAvg PriceValueShares OwnedFiling
Oct 15, 2024Oct 15 8:38 PMHeyman Richard A.
Proposed Sale
1,270$27.75$35.2K

View →

Oct 9, 2024Oct 9 8:27 PMLyssikatos Joseph P
Proposed Sale
12,000$28.01$336.1K

View →

Oct 9, 2024Oct 9 8:16 PMKintz Samuel
Proposed Sale
12,000$28.01$336.1K

View →

Oct 8, 2024Oct 8 7:59 PMBallal Rahul D.
Proposed Sale
10,420$27.45$286.0K

View →

Oct 4, 2024Oct 4 8:28 PMHeyman Richard A.
Proposed Sale
2,540$25.51$64.8K

View →

Oct 1, 2024Oct 1 8:14 PMHohl Benjamin
Proposed Sale
12,009$25.54$306.7K

View →

Sep 30, 2024Sep 30 8:19 PMHohl Benjamin
Proposed Sale
491$24.13$11.8K

View →

Apr 28, 2025Hohl Benjamin
Proposed Sale
3,250$18.21$59.2K

View →

← Previous

Page 7 of 7

Stock Options & Derivatives
Txn DateAcceptedInsiderTypeSharesExercise PriceShares OwnedFiling
Feb 12, 2026Feb 18 12:52 AMJoseph P LyssikatosCHIEF SCIENTIFIC OFFICER
Grant/Award
112,500$27.16112,500(D)

View →

Feb 12, 2026Feb 18 12:49 AMBenjamin HohlCHIEF FINANCIAL OFFICER
Grant/Award
150,000$27.16150,000(D)

View →

Feb 12, 2026Feb 18 12:47 AMHelen Louise CollinsCHIEF MEDICAL OFFICER
Grant/Award
150,000$27.16150,000(D)

View →

← Previous

Page 2 of 2